FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lesley Seymour

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Canada

Co-author Network

Publications

TOP 3
Sinead Cuffe; Caroline Domerg; Monia Ezzalfani; Stephen Graziano; Pasi A Janne; Jean-Pierre Pignon; Lesley Seymour; Abderrahmane Bourredjem; Ronald Burkes; Marzia Capelletti; Elizabeth Strevel; Ming-Sound Tsao; Frances A Shepherd
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.
Daniel J Renouf; Bernadette Southwood; David Walde; Wendy Walsh; Eric Chen; Isabelle Gauthier; Sharlene Gill; Rakesh Goel; David Hedley; Derek Jonker; Lynn McIntosh; Malcolm J Moore; Lesley Seymour
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Scott A Laurie; Christopher W Lee; Wojciech Morzycki; Nevin Murray; Garth Nicholas; Sanjay Rao; Tony Reiman; Delia Sauciuc; Jean Seely; Quincy Chu; Ronald Feld; Alison H Foo; John R Goffin; Ashish Gupta; Francis Laberge; Janessa Laskin; Lesley Seymour
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lesley Seymour (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sinead Cuffe; Caroline Domerg; Monia Ezzalfani; Stephen Graziano; Pasi A Janne; Jean-Pierre Pignon; Lesley Seymour; Abderrahmane Bourredjem; Ronald Burkes; Marzia Capelletti; Elizabeth Strevel; Ming-Sound Tsao; Frances A Shepherd
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(6):963-72.
2012: Daniel J Renouf; Bernadette Southwood; David Walde; Wendy Walsh; Eric Chen; Isabelle Gauthier; Sharlene Gill; Rakesh Goel; David Hedley; Derek Jonker; Lynn McIntosh; Malcolm J Moore; Lesley Seymour
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Investigational new drugs 2012;30(2):779-86.
2011: Scott A Laurie; Christopher W Lee; Wojciech Morzycki; Nevin Murray; Garth Nicholas; Sanjay Rao; Tony Reiman; Delia Sauciuc; Jean Seely; Quincy Chu; Ronald Feld; Alison H Foo; John R Goffin; Ashish Gupta; Francis Laberge; Janessa Laskin; Lesley Seymour
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11):1950-4.
2011: Ming Tsao; Akira Sakurada; Keyue Ding; Sarit Aviel-Ronen; Olga Ludkovski; Ni Liu; Aurélie Le Maître; David R Gandara; David H Johnson; James Rigas; Lesley Seymour; Frances A Shepherd
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):139-47.
2010: R Goodwin; Keyue Ding; Lesley Seymour; A LeMaître; Andrew Arnold; Frances A Shepherd; M Dediu; T Ciuleanu; D Fenton; M Zukin; D Walde; F Laberge; M Vincent; P M Ellis; S A Laurie
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2220-6.
2010: Chang-Qi Zhu; Keyue Ding; Dan Strumpf; Barbara A Weir; Matthew Meyerson; Nathan Pennell; Roman K Thomas; Katsuhiko Naoki; Christine Ladd-Acosta; Ni Liu; Melania Pintilie; Sandy D Der; Lesley Seymour; Igor Jurisica; Frances A Shepherd; Ming-Sound Tsao
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4417-24.
2010: Hal Hirte; Amit Oza; K Swenerton; S L Ellard; R Grimshaw; B Fisher; M Tsao; Lesley Seymour
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Gynecologic oncology 2010;118(3):308-12.
2010: Paul Wheatley-Price; Aurélie Le Maître; Keyue Ding; Natasha Leighl; Vera Hirsh; Lesley Seymour; Andrea Bezjak; Frances A Shepherd
The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(5):640-8.
2010: Martin D Forster; Nagahiro Saijo; Lesley Seymour; Hilary Calvert
Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1737-44.
2010: Patricia M LoRusso; Scott A Boerner; Lesley Seymour
An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1710-8.
2010: Michael Crump; David Hedley; Suzanne Kamel-Reid; Brian Leber; Richard Wells; Joseph Brandwein; Rena Buckstein; Janine Kassis; Mark Minden; John Matthews; Sue Robinson; Robert Turner; Lynn McIntosh; Elizabeth Eisenhauer; Lesley Seymour
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Leukemia & lymphoma 2010;51(2):252-60.
2010: Charles Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David R Gandara; David H Johnson; Kenneth A Kesler; Mark Green; mark vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):29-34.
2009: Raymond W Jang; Aurélie Le Maître; Keyue Ding; Timothy Winton; Andrea Bezjak; Lesley Seymour; Frances A Shepherd; Natasha B Leighl
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4268-73.
2009: Penelope Bradbury; Lesley Seymour
Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
Cancer journal (Sudbury, Mass.) 2009;15(5):354-60.
2009: Simon J Crabb; Demetris Patsios; Eric Sauerbrei; Peter M Ellis; Andrew Arnold; Glenwood Goss; Natasha B Leighl; Frances A Shepherd; Jean Powers; Lesley Seymour; Scott A Laurie
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(3):404-10.
2008: Wenjiang Zhang; Lesley Seymour; Eric X Chen
Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;876(2):277-82.
2008: Andrea Bezjak; Christopher W Lee; Keyue Ding; Michael D Brundage; Timothy Winton; Barbara Graham; Marlo Whitehead; David H Johnson; Robert B Livingston; Lesley Seymour; Frances A Shepherd
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5052-9.
2008: Chang-Qi Zhu; Gilda da Cunha Santos; Keyue Ding; Akira Sakurada; Jean-Claude Cutz; Ni Liu; Tong Zhang; Paula Marrano; Marlo Whitehead; Jeremy A Squire; Suzanne Kamel-Reid; Lesley Seymour; Frances A Shepherd; Ming-Sound Tsao
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4268-75.
2008: Martin Früh; Estelle Rolland; Jean-Pierre Pignon; Lesley Seymour; Keyue Ding; Hélène Tribodet; Timothy Winton; Thierry Le Chevalier; Giorgio V Scagliotti; Jean Yves Douillard; Stephen Spiro; Frances A Shepherd
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3573-81.
2008: K Ding; Joseph L Pater; M Whitehead; Lesley Seymour; Frances A Shepherd
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Contemporary clinical trials 2008;29(4):527-36.
2008: Marie Florescu; Baktiar Hasan; Lesley Seymour; Keyue Ding; Frances A Shepherd
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6):590-8.
2008: Jennifer J Knox; Sharlene Gill; Timothy W Synold; James J Biagi; Pierre Major; Ron Feld; Christine Cripps; Nancy Wainman; Elizabeth Eisenhauer; Lesley Seymour
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Investigational new drugs 2008;26(3):265-72.
2008: Paul Wheatley-Price; Keyue Ding; Lesley Seymour; Gary M Clark; Frances A Shepherd
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2350-7.
2008: Timothy R Asmis; Keyue Ding; Lesley Seymour; Frances A Shepherd; Natasha B Leighl; Timothy Winton; Marlo Whitehead; Johanna N Spaans; Barbara C Graham; Glenwood D Goss
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):54-9.
2007: Ming Tsao; Sarit Aviel-Ronen; Keyue Ding; Davina Lau; Ni Liu; Akira Sakurada; Marlo Whitehead; Chang-Qi Zhu; Robert Livingston; David H Johnson; James Rigas; Lesley Seymour; Timothy Winton; Frances A Shepherd
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5240-7.
2007: Andrew M Arnold; Lesley Seymour; Michael Smylie; Keyue Ding; Yee C Ung; Brian Findlay; Christopher W Lee; Marina Djurfeldt; Marlo Whitehead; Peter Ellis; Glenwood Goss; Adrien Chan; Jacinta Meharchand; Yasmin Alam; Richard Gregg; Charles Butts; Peter Langmuir; Frances A Shepherd
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4278-84.
2007: R Buckstein; Ralph M Meyer; Lesley Seymour; J Biagi; H Mackay; Scott A Laurie; Elizabeth Eisenhauer
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
Current oncology (Toronto, Ont.) 2007;14(4):154-61.
2007: Scott A Laurie; K Ding; M Whitehead; R Feld; N Murray; F A Shepherd; Lesley Seymour
The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(6):1051-5.
2007: Raymond Ng; Baktiar Hasan; Nicole Mittmann; Marie Florescu; Frances A Shepherd; Keyue Ding; Charles Butts; Yvon Cormier; Gail Darling; Glenwood Goss; Richard Inculet; Lesley Seymour; Timothy Winton; William K Evans; Natasha B Leighl
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2256-61.
2007: Carmela Pepe; Baktiar Hasan; Timothy Winton; Lesley Seymour; Barbara Graham; Robert B Livingston; David H Johnson; James R Rigas; Keyue Ding; Frances A Shepherd
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1553-61.
2007: I Gauthier; Keyue Ding; Timothy Winton; Frances A Shepherd; Robert Livingston; David H Johnson; James Rigas; Marlo Whitehead; Barbara Graham; Lesley Seymour
Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
Lung cancer (Amsterdam, Netherlands) 2007;55(3):357-63.
2007: Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming Tsao; Frances A Shepherd; Tony Reiman
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):994-9.
2006: Jean Maroun; K Belanger; Lesley Seymour; Sarah Matthews; J Roach; Jeanne Dionne; Denis Soulieres; D Stewart; Rakesh Goel; Danielle Charpentier; Glenwood Goss; Eva Tomiak; JC Yau; J Jimeno; G Chiritescu
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(9):1371-8.
2006: Andrea Bezjak; Dongsheng Tu; Lesley Seymour; Gary Clark; Aleksandra Trajkovic; Mauro Zukin; Joseph Ayoub; Sergio Lago; Ronaldo de Albuquerque Ribeiro; Alexandra Gerogianni; Arnold Cyjon; Jonathan Noble; Francis Laberge; Raymond Tsz-Tong Chan; David Fenton; Joachim von Pawel; Martin Reck; Frances A Shepherd
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):3831-7.
2006: Ignacio Duran; Lillian L Siu; Amit Oza; T-B Chung; Jeremy F G Sturgeon; Carol A Townsley; Gregory R Pond; Lesley Seymour; M Niroumand
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.
European journal of cancer (Oxford, England : 1990) 2006;42(12):1875-80.
2006: H Hirte; I B Vergote; J R Jeffrey; R N Grimshaw; S Coppieters; B Schwartz; Dongsheng Tu; Anna Sadura; M Brundage; Lesley Seymour
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
Gynecologic oncology 2006;102(2):300-8.
2006: Jean Maroun; Derek Jonker; Lesley Seymour; Rakesh Goel; mark vincent; W Kocha; C Cripps; Bryn Fisher; D Lister; A Malpage; G Chiritescu
A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2006;42(2):193-9.
2005: Eric X Chen; Gerald Batist; Lillian L Siu; Naeema Bangash; Martha Maclean; Lynn McIntosh; Wilson H Miller; Amit Oza; Chetan Lathia; Oana Petrenciuc; Lesley Seymour
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
Investigational new drugs 2005;23(5):455-65.
2005: Karen Gelmon; Karl Belanger; Denis Soulieres; Carolyn Britten; Stephen Chia; Danielle Charpentier; Kim Chi; Jean Powers; Wendy Walsh; Lesley Seymour
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.
Investigational new drugs 2005;23(5):445-53.
2005: Massimo Di Maio; Cesare Gridelli; Ciro Gallo; Frances A Shepherd; Francovito Piantedosi; Silvio Cigolari; Luigi Manzione; Alfonso Illiano; Santi Barbera; Sergio Federico Robbiati; Luciano Frontini; Elena Piazza; Giovanni Pietro Ianniello; Enzo Veltri; Federico Castiglione; Francesco Rosetti; Vittorio Gebbia; Lesley Seymour; Paolo Chiodini; Francesco Perrone
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.
The lancet oncology 2005;6(9):669-77.
2005: John Goffin; Stefan David Baral; Dongsheng Tu; Dora Nomikos; Lesley Seymour
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5928-34.
2005: Lyly H Lê; Malcolm J Moore; Lillian L Siu; Amit Oza; Martha Maclean; Bryn Fisher; Ajai Chaudhary; Dinesh P de Alwis; Christopher A Slapak; Lesley Seymour
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 2005;56(2):154-60.
2005: Ming Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
The New England journal of medicine 2005;353(2):133-44.
2005: Frances A Shepherd; José Rodrigues Pereira; tudor ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Erlotinib in previously treated non-small-cell lung cancer.
The New England journal of medicine 2005;353(2):123-32.
2005: Susan Dent; A Arnold; D J Stewart; Stan Gertler; Joseph Ayoub; Gerald Batist; G Goss; A Nevile; Denis Soulieres; Jacques Jolivet; L McLntosh; Lesley Seymour
Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
Lung 2005;183(4):265-72.
2005: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming Tsao; David R Gandara; Kenneth Kesler; Todd L Demmy; Frances A Shepherd
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
The New England journal of medicine 2005;352(25):2589-97.
2005: Eric Winquist; Malcolm J Moore; Kim N Chi; D Scott Ernst; Hal Hirte; Scott North; Jean Powers; Wendy Walsh; Therese Boucher; Robert Patton; Lesley Seymour
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
Urologic oncology 2005;23(3):143-9.
2005: Natasha B Leighl; Luis Paz-Ares; Jean-Yves Douillard; Christian Peschel; Andrew Arnold; Alain Depierre; Armando Santoro; Daniel C Betticher; Ulrich Gatzemeier; Jacek Jassem; Jeffrey Crawford; Dongsheng Tu; Andrea Bezjak; Jeff Humphrey; Maurizio Voi; Susan Galbraith; Katherine Hann; Lesley Seymour; Frances A Shepherd
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2831-9.
2005: Mary J Mackenzie; Hal Hirte; Goss Glenwood; Maroun Jean; Rakesh Goel; Pierre P Major; Wilson H Miller; Lawrence Panasci; Ian A J Lorimer; Gerald Batist; Sarah Matthews; Lynn Douglas; Lesley Seymour
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Investigational new drugs 2005;23(2):165-70.
2005: Naveed Alam; Frances A Shepherd; Timothy Winton; Barbara Graham; David Johnson; Robert Livingston; James Rigas; Marlo Whitehead; Keyue Ding; Lesley Seymour
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Lung cancer (Amsterdam, Netherlands) 2005;47(3):385-94.
2005: Christina M Canil; Malcolm J Moore; Eric Winquist; Tara Baetz; M Pollak; Kim N Chi; S Berry; DS Ernst; L Douglas; Michael D Brundage; Bryn Fisher; A McKenna; Lesley Seymour
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):455-60.
2005: Rakesh Goel; E Chouinard; David J Stewart; SD Huan; Hal Hirte; S Stafford; B Waterfield; J Roach; Chetan Lathia; V Agarwal; R Humphrey; Wendy Walsh; Sarah Matthews; Lesley Seymour
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Investigational new drugs 2005;23(1):63-71.
2005: Georg A Bjarnason; Danielle Charpentier; Ralph Wong; Rakesh Goel; Lynn Douglas; Wendy Walsh; Sarah Matthews; Susan Dent; Lesley Seymour; Eric Winquist
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).
Investigational new drugs 2005;23(1):51-6.
2004: Jean-Yves Douillard; Christian Peschel; Frances A Shepherd; Luis Paz-Ares; Andrew Arnold; Mary Davis; Maurizio Tonato; Michael Smylie; Dongsheng Tu; Maurizio Voi; Jeffrey Humphrey; Jon Ottaway; Katherine Young; Anne Van Vreckem; Lesley Seymour
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46(3):361-8.
2004: Leonard Reyno; Lesley Seymour; Dongsheng Tu; Susan Dent; Karen Gelmon; Barbara Walley; Anna Pluzanska; Vera Gorbunova; Avgust Garin; Jacek Jassem; Tadeusz Pienkowski; Janet Dancey; Laura Pearce; Mary MacNeil; Susan Marlin; David Lebwohl; Maurizio Voi; Kathleen Pritchard
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(2):269-76.
2003: Theodora Voskoglou-Nomikos; Joseph L Pater; Lesley Seymour
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4227-39.
2003: Malcolm J Moore; J Hamm; Janet E Dancey; P D Eisenberg; M Dagenais; A Fields; K Hagan; B Greenberg; B Colwell; Benny Zee; Dongsheng Tu; Jon Ottaway; R Humphrey; Lesley Seymour
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3296-302.
2003: Cesare Gridelli; Ciro Gallo; Frances A Shepherd; Alfonso Illiano; Francovito Piantedosi; Sergio Federico Robbiati; Luigi Manzione; Santi Barbera; Luciano Frontini; Enzo Veltri; Brian Findlay; Silvio Cigolari; Robert Myers; Giovanni Pietro Ianniello; Vittorio Gebbia; Giampietro Gasparini; Sergio Fava; Vera Hirsh; Andrea Bezjak; Lesley Seymour; Francesco Perrone
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3025-34.
2003: Manijeh Daneshmand; Doris A E Parolin; Hal Hirte; Pierre Major; Glenwood Goss; David Stewart; Gerald Batist; Wilson H Miller; Sarah Matthews; Lesley Seymour; Ian A J Lorimer
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2457-64.
2003: Lesley Seymour
Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics.
Current opinion in investigational drugs (London, England : 2000) 2003;4(6):658-66.
2003: Carol A Townsley; Kim Chi; D S Ernst; Karl Belanger; Ian F Tannock; G A Bjarnason; D Stewart; R Goel; J D Ruether; Lillian L Siu; Jacques Jolivet; Lynn McIntosh; Lesley Seymour; Malcolm J Moore
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1524-9.
2002: Frances A Shepherd; Giuseppe Giaccone; Lesley Seymour; Channa Debruyne; Andrea Bezjak; Vera Hirsh; Michael Smylie; Sheldon Rubin; Heidi Martins; Alan Lamont; Maciej Krzakowski; Anna Sadura; Benny Zee
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4434-9.
2002: R G Tozer; Susan Burdette-Radoux; K Berlanger; M L Davis; Reinhard Lohmann; J R Rusthoven; Nancy Wainman; B Zee; Lesley Seymour
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Investigational new drugs 2002;20(4):407-12.
2002: Karl Bélanger; Malcolm Moore; Sharyn D Baker; Jeanne Dionne; Martha Maclean; Jacques Jolivet; Lillian Siu; Denis Soulières; Nancy Wainman; Lesley Seymour
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2567-74.
2002: Marc Trudeau; Gavin Stuart; Hal Hirte; Pierre Drouin; Marie Plante; Paul Bessette; Hélène Dulude; David Lebwohl; Bryn Fisher; Lesley Seymour
A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
Gynecologic oncology 2002;84(2):327-31.
2002: Lesley Seymour
The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
Current pharmaceutical design 2002;8(25):2279-84.
2001: M Knowling; George Browman; Lillian Siu; K Khoo; A Cooke; I Tannock; D Klaassen; C Cripps; Glenwood Goss; Sarah Matthews; R Clarke; Lesley Seymour
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):919-22.
2001: Lesley Seymour; E Eisenhauer
A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
Cancer chemotherapy and pharmacology 2001;47(1):2-10.
2000: Hal Hirte; Rakesh Goel; P Major; Lesley Seymour; SD Huan; David Stewart; JC Yau; A Arnold; S Holohan; B Waterfield; S Bates; K Bennett; Wendy Walsh; I Elias
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1579-84.
2000: Stan Gertler; D MacDonald; M Goodyear; Peter A Forsyth; David J Stewart; K Belanger; J Perry; D Fulton; W Steward; Nancy Wainman; Lesley Seymour
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):315-8.
1999: Malcolm J Moore; Eric Winquist; N Murray; I F Tannock; SD Huan; K Bennett; Wendy Walsh; Lesley Seymour
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2876-81.